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Abstract
Background: The aim of this study was to evaluate the biological and pharmaceutical activities of 14 amphiphilic
liquid-crystalline compounds (LCs), i.e, phenylpyrimidine derivatives possessing D-glucamine and cyanobiphenyl
derivatives with a terminal hydroxyl unit.
Results: The cytotoxic properties of the LCs on the cell growth, cell cycle distribution, and cell signaling pathway
of U937 human leukemic monocyte lymphoma cells were assessed by flow cytometry and western blot analysis.
Some LCs showed cytostatic effects, suppressing cell growth via S-phase arrest and without apoptosis in U937
cells. To investigate the mechanisms of the LC-induced S-phase arrest, proteins relevant to cell cycle regulation
were investigated by western blot analysis. The rate of LC-induced S-phase arrest was congruent with the
decreased expression of MCM2, cyclin A, cyclin B, CDK2, phospho-CDK1 and Cdc25C. Observed changes in cell
cycle distribution by LC treated might be caused by insufficient preparation for G2/M transition. Considering the
structure of the LCs, the rod-like molecules displaying cytotoxicity against U937 cells possessed flexible spacers
with no bulky polar group attached via the flexible spacer.
Conclusions: Our results revealed that some LCs showed cytotoxic properties against non-solid type tumor human
leukemic cells via LC-induced S-phase arrest and decreasing expression of several cell cycle related proteins.
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Background
Chemotherapy can regulate the uncontrolled prolifera-
tion of abnormal cancer cells by using various types of
drugs. The majority of chemotherapeutic drugs can be
divided into categories, including the alkylating agents,
antimetabolites, anthracyclines, plant alkaloids, topoi-
somerase inhibitors, monoclonal antibodies, and other
antitumor agents [1-7]. Although several types of che-
motherapeutic agents have been developed recently,
such as molecular targetting drugs, the tyrosine kinase
inhibitor Imatinib, only few drugs may result in com-
plete recovery of cancer patients. Therefore, it is essen-
tial to develop novel drugs for cancer treatment.
Liquid-crystalline compounds (LCs) are widely used in
display media in televisions and personal computers.
LCs are classified into various categories on the basis of
their structural characteristics. One of the principal
compounds is an amphiphilic compound, consisting of
hydrophobic and hydrophilic components. Amphiphilic
liquid crystals are thought to have structural affinity to
the cell membranes, which are lamellar bilayer meso-
phases of phospholipids, glycolipids, and cholesterol.
Therefore, some lyotropic LCs displaying a structural
affinity to the cell membranes have been applied for the
development of novel drug delivery systems [3].
Although these amphiphilic LCs seem promising for
biological applications, the pharmacological properties
of LCs are not well understood, and therefore, must be
elucidated.
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LC materials, namely, the phenylpyrimidine and cyano-
biphenyl derivatives, showed cytostatic effects on the
growth of solid tumor A549 human lung cancer cells,
causing G1-phase arrest in cells. One of the phenylpyri-
midine derivatives inhibited A549 growth without any
toxicity to normal fibroblasts [8,9]. However, it is not
yet known whether these LCs have cytotoxic properties
against non-solid type tumor leukemic cells that are
commonly treated by chemotherapy. To clarify this
issue, we investigated the cytotoxic properties of 14
amphiphilic LCs against the human leukemic monocyte
lymphoma cell line U937.
Results
Screening of LCs with respect to the cytotoxicity against
U937 cells
The effect of each compound (10 μM) on the growth of
the U937 cells was tested to investigate the cytotoxic
properties of the LCs shown in Table 1. Compound #8,
which contains a cyanobiphenyl in its central position,
and compound #13, which contains a phenylpyrimidine,
showed the maximum suppressive effect among all the
compounds tested herein (Figure 1). Therefore, subse-
quent studies were performed using compounds #8 and
#13 to characterize their suppressive mechanisms on the
growth of U937 cells.
To determine the growth inhibitory profiles for #8 and
#13 on U937 cells, proliferation assays were performed
a tv a r i o u st i m ep o i n t sa n dc o n c e n t r a t i o n s .B o t hc o m -
pounds #8 and #13 exhibited cytotoxic properties in a
time-dependent manner (Figure 2A). The IC50 values of
compounds #8 and #13 were 6.8 and 6.3 μM, respec-
tively (Figures 2B, C). Therefore, subsequent experi-
ments were mainly performed using the determined
IC50 values.
Effects of LCs on apoptosis and cell cycle distribution
During the early stages of apoptosis, translocation of
phosphatidylserine (PS) to the cell surface is a key signal
in the apoptotic pathway. Annexin V is a Ca
2+-depen-
dent phospholipid-binding protein with high affinity for
P S[ 1 0 ] .T h e r e f o r e ,t oe l u c i d a t ew h e t h e ra p o p t o t i c
induction is involved in the cytotoxic property of LCs,
cells were analyzed by flow cytometry using Annexin V-
FITC and PI staining (Figure 3). Although each of the
LCs induced 50% growth suppression, indiscernible
changes were observed between the control and LC-
treated groups in each fraction (each Annexin V-posi-
tive/PI-negative fraction of control, #8 and #13 was 1.5%
and 1.8%, respectively). These data indicate that the
cytotoxic properties of LCs are not related to apoptotic
and necrotic induction of cell death.
S-phase arrest by LCs in the cell cycle of U937 cells
Since anti-tumor drugs usually affect the cell cycle dis-
tribution [11], the cell cycle distribution in U937 cells
treated with LCs was analyzed by flow cytometry. As
shown in Figure 4A, no modification of the cell cycle
distribution was observed in LCs-treated cells compared
to the controls at 3 h. However, LCs significantly
induced the S-phase population at 6 and 12 h (Figure
4B). These data indicated that LCs induced S-phase
arrest in U937 cells.
Table 1 Structure of liquid crystalline compounds
Sample Number Structural formula
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
#13
#14
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related to cell cycle progression by LCs in U937 cells
To investigate the mechanism of S-phase arrest induc-
tion by LCs, proteins relevant to cell cycle regulation
were evaluated by western blot analysis of U937 cells
treated with compounds #8 and #13 (Figure 5). CDK2
and cyclin E are known to regulate progression through
G1/S transition [12,13], and MCM2 is required in the
acquisition of DNA replication fork [14,15]. Cyclin A is
required for both progression S phase and M phase
[16]. Activation of CDK1 regulate entry into mitosis,
and is controlled at several steps including cyclin B
binding and dephosphorylation of CDK1 at Thr 14/
Tyr15 by Cdc25C phosphatase [17-19]. As shown in Fig-
ure 5, the expression of MCM2 was decreased by LC
treatment at 1 h, and the expression of cyclin A, cyclin
E, CDK2 were decreased by LC treatment at 1-6 h. In
addition, the expression of Cdc25C was decreased by
LC treatment at 6 h, and the expression of phospho-
CDK1 (Tyr 15) was decreased by LC treatment at 1-6 h.
Discussion
The pharmaceutical activities of 14 amphiphilic LCs
were examined in human leukemic monocyte lymphoma
U937 cells (Table 1). Some LCs (#5, #8, #10-13) showed
cytotoxic properties (Figure 1). Among the LCs tested,
c o m p o u n d s# 8a n d# 1 3s h o w e dm a r k e dc y t o t o x i c i t y ,
and the IC50 values of these compounds were similar
(6.8 and 6.3 μM, respectively) (Figure 2). However, cyto-
toxic effects by these compounds had no relation to
apoptosis induction supported by Annexin V/PI staining
analysis (Figure 3). Both compounds were considered to
delay S-phase progression in cell cycle, through inhibi-
tion of MCM2, cyclin A, cyclin B, CDK2, phospho-
CDK1 (Tyr15) and Cdc25C expression (Figures 4, 5).
The cell cycle is a fundamental and ordered event in
which DNA replicates, and homologous chromosomes
segregate and equally distributed among the daughter
cells. Therefore, the oscillation of specific protein
expressions is important in cell cycle progression. The
tyrosine phosphatase Cdc25C serve as mitotic activator
through dephosphorylation of CDK1 at Tyr14/15 and is
negatively regulated by phosphorylation at Ser216.
Because LCs is considered to prevent S-phase progres-
sion through MCM2 inhibition and insufficient cyclin
proteins, decreased phospho-CDK1 (Tyr15) might
reflect the failure of Tyr15 phosphorylation by Wee1 in
G2 phase. Therefore, majority of CDK1 exist as inacti-
vated form comparing to control and both Cdc25C and
phos-Cdc25C (Ser216) decrease imply mere lack of pre-
paration for cell cycle progression. Similar phenomenon
were reported that reducing cyclin A/CDK2 and
Cdc25C expressions lead to S phase arrest in human
Lovo colon cancer cells [19].
The cytotoxic property and classes of active com-
pound depend on cell types because compounds cyto-
toxic to U937 cells (#5, #8, #10-13) are not necessarily
cytotoxic to other cell types, lung cancer A549 cells [8].
Compounds #5, #10, #12, and #13 had little effects
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Figure 2 Suppressive effects of the liquid crystalline
compounds #8 and #13 on the growth of U937 cells. [A] Cells
were treated with 6-7 μM liquid crystalline compounds or DMSO for
the indicated periods. [B] The dose response curves of U937 cells to
liquid crystalline compounds. Activity shows growth inhibition rate.
The IC50 values were determined using the Boltzmann functions.
Values are the mean ± standard deviation (S.D.) value of more than
3 separate experiments in duplicate wells.
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Figure 1 Screening of LCs with respect to the cytotoxicity
against U937 cells. Effects of liquid crystalline compounds on the
growth of theU937 human leukemic monocyte lymphoma cell line.
The cells were cultured in liquid medium containing 10 μM of each
compound for 48 h. *p < 0.05 using Student’s t-test.
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phase arrest observed present study but G1-phase arrest
in A549 cells without apoptosis [8]. Nevertheless, apop-
tosis unrelated toxicity is common feature of compound
#8, which is supporsed torelate with p53 independent
mechanism because A549 and U937 cells have valid p53
genomic contexts [20,21]. The loss of p53 function gen-
erally leads to resistance to chemotherapeutic drugs,
tumor malignancy and metastasis [22], therefore, com-
pound #8 could be an effective drug against a variety of
tumors regardless of p53 status.
The structure of LCs may be responsible for the cell-
specific cytotoxic effects exerted by the different LCs.
For example, #11, in which D-glucamine and phenylpyr-
imidine are connected via a flexible spacer, displayed a
strong cytotoxic effect against A549 cells, but showed
only a moderate cytotoxic effect against U937 cells.
Compound #13, in which D-glucamine was removed
from #11, did not exert cytotoxic effects against A549
cells; however, it showed a strong cytotoxic effect
against U937 cells. These results suggest that differences
in the molecular structures of the LCs were responsible
for the differences in their cell type-specific inhibitory
effect. Previously, Takahashi et al. demonstrated that
the suppressive effects of cyanobiphenyl derivatives on
A549 cells depended on alkyl chain length rather than
on the terminal substrate or the position of hydroxyl
moieties [8]. Interestingly, both compounds #8 and #13,
which showed strong cytotoxic effects against U937
cells, possess -O(CH2)6OH in their structure. Further-
more, the compounds that had cytotoxic activity against
U937 cells (#5, #8, #10, #11, and #13) were structured
as rod-like molecules. These rod-like molecules possess
a flexible spacer consisting of an alkyl chain such as
(CH2)6 and are not attached to a bulky polar group
such as -OH, -CN, and -COOH via this flexible spacer.
These structures might play an important role in the
cytotoxic effects against U937 by LCs. Further, studies
are necessary to elucidate the structure-activity
relationships.
It remains unclear how active LC compounds inhib-
ited expression of several cell cycle related proteins.
However, LCs clearly suppressed the growth of tumor
cells independent of p53. In addition, the cytotoxicity of
compound #8 is enhanced by mixing another LC at an
equimolar concentration, which is suspected to result in
an antiparallel molecular alignment via a dipole-dipole
interaction [23]. Because anti-cancer drugs used at clini-
cal situation remains several problems including phar-
macological tolerance and secondary effect, further
studies are clearly required to elucidate LC’s structural
properties and its pharmacological activity.
Conclusion
In this study, some LCs showed cytostatic effects, sup-
pressing cell growth via S-phase arrest and without
apoptosis in U937 cells. Furthermore, LCs clearly sup-
pressed the growth of tumor cells independent of p53.
Our results suggest that some LCs possessing cytotoxic
properties may be useful for cancer treatments irrespec-
tive of their p53 status.
Methods
Liquid crystal compounds
Compound #1 was provided by Midori Kagaku Co., Ltd.
(Tokyo, Japan). Compound #2 was provided by Japan
Energy Corporation (Tokyo, Japan) and compound #3
was purchased from the Kanto Chemical Co., Ltd.
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Figure 3 Analysis of apoptosis in U937 cells. The cells were treated with IC50 value of the compounds #8 and #13 or DMSO for 48 h. The x-
axis indicates the Annexin V-positive populations, and the y-axis indicates the propidium iodide-positive populations.
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Page 4 of 7(Tokyo, Japan). The other compounds in Table 1 were
synthesized in our laboratory.
Each compound was dissolved in dimethyl sulfoxide
(DMSO; Wako, Osaka, Japan) at 0.1 mM, 1 mM, and 10
mM concentrations, respectively. Each dissolved com-
pound was stored at 4°C in the dark.
Antibodies
Anti-minichromosome maintenance (MCM2) antibody
(Rabbit, #2901-1), anti-cell division cycle 25 C (Cdc25C)
antibody (Rabbit, #1302-1), and anti-phospho Cdc25C
(Ser216) antibody (Rabbit, #1190-1) were purchased
from Epitomics Inc. (California, USA). Anti-actin anti-
body (Goat, C-11, sc-1615) and anti-cyclin dependent
kinase 2 (CDK2) antibody (Rabbit, sc-163) were pur-
chased from Santa Cruz Biotechnology (Santa Cruz,
California, USA). Anti-cyclin E antibody (Mouse,
#4129), anti-cyclin A (BF683) antibody (Mouse, #4656),
anti-cyclin B1 (V152) antibody (Mouse, #4135), and
anti-phospho cdc2 (Tyr15) antibody (Rabbit, #9111S)
were purchased from Cell Signaling Technology (Tokyo,
Japan).
Cell line
The U937 human leukemic monocyte lymphoma cell
line was purchased from the RIKEN Bio-Resource Cen-
ter (Tsukuba, Japan). This cell was maintained in con-
tinuous culture in RPMI1640 medium (Gibco
®,
Invitrogen, California, USA) supplemented with 10%
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Figure 5 Western blot profiles of cell cycle-related molecules
in the U937 cells. [A and B] Western blot profiles of cell cycle-
related molecules in the U937 cells treated with IC50 value of the
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Figure 4 Effect of liquid crystalline compounds on the cell
cycle distribution in U937 human leukemic monocyte
lymphoma cells. [A] Flow cytometry analysis of U937 cells treated
with each compounds for indicated times. Representative
cytograms are shown. [B] The rate of S-phase in U937 cells was
shown. Values are the mean ± standard deviation (S.D.) value of at
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Page 5 of 7heat-inactivated fetal bovine serum (Bioserum, UBC,
Japan) in a humidified atmosphere at 37°C and 5% CO2.
Cell growth inhibition assay
In the first screening, the U937 cells were seeded in a
24-well tissue culture plate (Falcon, Becton Dickinson
Biosciences, Franklin Lakes, USA) with 500 μl of culture
medium at a concentration of 5 × 10
4 cells/well, and
each LC was added to the culture at a concentration of
10 μM. After 48 h incubation, cells at each condition
were harvested, and diluted in trypan blue (Nacalai Tes-
que, Kyoto, Japan), which distinguishes viable cells from
the damaged or dead ones. Cell growth was investigated
by microscopy, and counting of viable cells was con-
ducted using Burker-Turk hemocytometer (SLGC, Sai-
tama, Japan). The relative value normalized to control
values was calculated as the ratio of the number of LC-
treated cells to the number of control cells. In the deter-
mination of 50% inhibitory concentration (IC50), the
U937 cells were seeded in a 48-well tissue culture plate
(Falcon) with 200 μl of culture medium at a concentra-
tion of 1 × 10
4 cells/well, and each LC was added to the
culture at various concentrations ranging from 1.5 to 30
μM. After 48 h incubation, cells at each condition were
harvested, and the number of viable cells was counted
by the trypan blue exclusion test under a microscope.
The relative value normalized to control values was cal-
culated as the ratio of the number of LC-treated cells to
the number of control cells.
Detection of apoptosis by flow cytometry
The extent of apoptosis was determined by Annexin V-
FITC and propidium iodide (PI) staining according to
the manufacturer’s instructions. In brief, the cells were
suspended with 100 μl of binding buffer (10 mM
HEPES/NaOH, 140 mM NaCl, 2.5 mM CaCl2;p H7 . 4 )
and stained with Annexin V-FITC for 10 min at room
temperature in the dark. After washing with binding
buffer, the cells were re-suspended in binding buffer
containing PI (20 μg/ml). Apoptotic cells were deter-
mined using the Cell Lab Quanta™ SC MPL apparatus.
In the Annexin V/PI quadrant gating, AnnexinV(-)/PI
(-), AnnexinV(-)/PI(+), AnnexinV(+)/PI(-), and Annex-
inV(+)/PI(+) represented the fraction of viable cells,
necrotic cells, early apoptotic cells, and late apoptotic/
secondary necrotic cells, respectively.
Cell cycle analysis by flow cytometry
The U937 cells were treated with each of the LCs in a
tissue culture dish (Iwaki, Chiba, Japan), according to
the method described above. After 3, 6, and 12 h of
treatment, the harvested cells were treated with PBS
containing 0.1% Triton X-100 (Wako) and stained with
propidium iodide (50 μg/ml; Sigma). An analysis of the
cell cycle distribution was performed using a flow cyt-
ometer (Quanta SC MPL; Beckman-Coulter, Fullerton,
California, USA).
SDS-PAGE and western blot analysis
SDS-PAGE and western blot analysis were performed as
described in previous reports [24]. Briefly, U937 cells
were treated with each compound in the medium and
incubated for the indicated times. The harvested cells
were lysed with 50 mM Hepes-HCl (pH 7.4), 100 mM
NaCl, 1% Triton X-100, and 1 mM PMSF (Wako) on ice
for 30 min, and sonicated twice for 30 s at ice-cold tem-
perature. After centrifugation at 12,000 rpm for 20 min
at 4°C, the protein concentration in the supernatant was
determined with a Bio-Rad Protein Assay Kit (Bio-Rad
Lab, Hercules, California, USA) using a SmartSpec™
Plus (Bio-Rad). Each protein lysate was mixed with 2 ×
sample buffer (625 mM Tris-HCl, pH6.8, 20% SDS, 2% 2-
mercaptoethanol, 2% glycerol). Each sample (30-50 μg/
lane) was separated by SDS-PAGE after boiling for 5
min. Next, the proteins in the gel were transferred to a
nitrocellulose membrane (Toyo Roshi, Tokyo, Japan).
The membrane was reacted with each primary antibody
in Tris-buffered saline (10 mM Tris-HCl, pH 7.4, 100
mM NaCl, 0.1% Tween-20), and supplemented with 5%
BSA or milk for 1 h at room temperature. After exposure
to the primary antibody, membranes were labeled with
donkey anti-rabbit IgG-HRP or anti-goat IgG-HRP anti-
body (Santa Cruz) or anti-mouse IgG-HRP antibody (R
and D Systems, Minneapolis, USA) and the antigens were
detected using ECL Plus Western Blotting Detection
Reagents (GE Healthcare Japan, Tokyo, Japan).
Statistical analysis
The significance of the differences between the control
and experimental groups were determined by Student’s
t-test or Mann-Whitney’s U-test depending on the dis-
tribution. Statistically significant differences were
defined as p-values of less than 0.05.
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